Item Type | Name |
Concept
|
Age Factors
|
Concept
|
alpha-Glucosidases
|
Concept
|
Academic Medical Centers
|
Concept
|
Fabry Disease
|
Concept
|
Aldosterone
|
Concept
|
Algorithms
|
Concept
|
Blood Pressure
|
Concept
|
Alleles
|
Concept
|
Amino Acid Sequence
|
Concept
|
Administration, Oral
|
Concept
|
Adrenergic beta-Antagonists
|
Concept
|
Albuminuria
|
Concept
|
Alcohol Drinking
|
Concept
|
Asia
|
Concept
|
Calcium Phosphates
|
Concept
|
Intracranial Aneurysm
|
Concept
|
Animals, Newborn
|
Concept
|
Aorta
|
Concept
|
Chromosomes, Human, Pair 11
|
Concept
|
Chromosomes, Human, Pair 2
|
Concept
|
Anthropometry
|
Concept
|
Bayes Theorem
|
Concept
|
Benzoates
|
Concept
|
Aspartate Aminotransferases
|
Concept
|
Body Height
|
Concept
|
Basement Membrane
|
Concept
|
Calcium Oxalate
|
Concept
|
Bilirubin
|
Concept
|
Bicarbonates
|
Concept
|
Body Weight
|
Concept
|
Career Mobility
|
Concept
|
Chlorthalidone
|
Concept
|
Chromosomes, Human, Pair 12
|
Concept
|
Creatinine
|
Concept
|
Cholesterol
|
Concept
|
Contrast Media
|
Concept
|
Coronary Artery Disease
|
Concept
|
Demography
|
Concept
|
Diabetes Mellitus, Type 2
|
Concept
|
Insulin
|
Concept
|
Cytochrome P-450 Enzyme System
|
Concept
|
Echocardiography
|
Concept
|
Image Enhancement
|
Concept
|
Chromosomes, Human, Pair 17
|
Concept
|
Clinical Protocols
|
Concept
|
Cross-Sectional Studies
|
Concept
|
Faculty, Medical
|
Concept
|
Fructokinases
|
Concept
|
Georgia
|
Concept
|
Family Relations
|
Concept
|
Fasting
|
Concept
|
Fibroblast Growth Factors
|
Concept
|
Hydrochlorothiazide
|
Concept
|
Fluorescent Antibody Technique
|
Concept
|
Gadolinium
|
Concept
|
Peptidyl-Dipeptidase A
|
Concept
|
Microfilament Proteins
|
Concept
|
Pharmacogenetics
|
Concept
|
Organ Size
|
Concept
|
Morbidity
|
Concept
|
Iothalamic Acid
|
Concept
|
Oxidation-Reduction
|
Concept
|
Cholesterol, HDL
|
Concept
|
Muscle Proteins
|
Concept
|
Nephritis, Hereditary
|
Concept
|
Potassium
|
Concept
|
Physicians' Offices
|
Concept
|
Image Processing, Computer-Assisted
|
Concept
|
Recurrence
|
Concept
|
Research Support as Topic
|
Concept
|
Risk Factors
|
Concept
|
Cohort Studies
|
Concept
|
Renal Artery
|
Concept
|
Sodium
|
Concept
|
Japan
|
Concept
|
Kininogens
|
Concept
|
Body Mass Index
|
Concept
|
Incidence
|
Concept
|
Cluster Analysis
|
Concept
|
Software
|
Concept
|
Syndrome
|
Concept
|
Sequence Homology, Amino Acid
|
Concept
|
Lipase
|
Concept
|
Randomized Controlled Trials as Topic
|
Concept
|
Cytochrome P-450 CYP11B2
|
Concept
|
Cell Adhesion Molecules
|
Concept
|
Prevalence
|
Concept
|
Observer Variation
|
Concept
|
Antigens, CD
|
Concept
|
Mortality
|
Concept
|
Chi-Square Distribution
|
Concept
|
N-Acetylgalactosaminyltransferases
|
Concept
|
Case-Control Studies
|
Concept
|
Angiopoietin-2
|
Concept
|
Hypertrophy, Left Ventricular
|
Concept
|
Amlodipine
|
Concept
|
Patient-Centered Care
|
Concept
|
Disease Progression
|
Concept
|
Receptors, Adrenergic, beta-2
|
Concept
|
Cytochrome P-450 CYP2D6
|
Concept
|
G-Protein-Coupled Receptor Kinase 4
|
Concept
|
Lipopolysaccharide Receptors
|
Concept
|
Ethnopharmacology
|
Concept
|
Molecular Diagnostic Techniques
|
Concept
|
Proteomics
|
Concept
|
Hypoxia-Inducible Factor 1, alpha Subunit
|
Concept
|
Area Under Curve
|
Concept
|
Parents
|
Concept
|
Internet
|
Concept
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Concept
|
Heterotrimeric GTP-Binding Proteins
|
Concept
|
Interleukin-18
|
Concept
|
Organic Cation Transport Proteins
|
Concept
|
Renin
|
Concept
|
Cystatin C
|
Concept
|
Obesity, Abdominal
|
Concept
|
CCAAT-Enhancer-Binding Protein-delta
|
Concept
|
Republic of Korea
|
Concept
|
Epithelial Sodium Channels
|
Concept
|
Medication Therapy Management
|
Concept
|
Receptor-Like Protein Tyrosine Phosphatases, Class 2
|
Concept
|
DNA Copy Number Variations
|
Concept
|
Workload
|
Concept
|
Caregivers
|
Concept
|
Adrenergic beta-1 Receptor Antagonists
|
Concept
|
Survival Rate
|
Concept
|
Receptors, Adrenergic, beta-1
|
Concept
|
Urinalysis
|
Concept
|
Chemokine CCL2
|
Concept
|
Imaging, Three-Dimensional
|
Concept
|
Homeodomain Proteins
|
Concept
|
Gadolinium DTPA
|
Concept
|
ADP-ribosyl Cyclase
|
Concept
|
Transcriptome
|
Concept
|
Genome-Wide Association Study
|
Concept
|
Metabolomics
|
Concept
|
Precision Medicine
|
Concept
|
Qualitative Research
|
Concept
|
Plasma Membrane Calcium-Transporting ATPases
|
Concept
|
Calcium Channel Blockers
|
Concept
|
Cell Line
|
Concept
|
Cells, Cultured
|
Concept
|
Chromosomes, Human, Pair 16
|
Concept
|
Clinical Trials as Topic
|
Concept
|
Diabetes Mellitus
|
Concept
|
Diastole
|
Concept
|
Diet, Sodium-Restricted
|
Concept
|
Disease Models, Animal
|
Concept
|
Epoxide Hydrolases
|
Concept
|
Fellowships and Scholarships
|
Concept
|
Follow-Up Studies
|
Concept
|
Genetic Testing
|
Concept
|
Health Status
|
Concept
|
Kidney Calculi
|
Concept
|
Longitudinal Studies
|
Concept
|
Prospective Studies
|
Concept
|
Receptors, Adrenergic, beta
|
Concept
|
Retrospective Studies
|
Concept
|
Urine
|
Concept
|
Gastric Bypass
|
Concept
|
Focus Groups
|
Concept
|
Cost of Illness
|
Concept
|
Age of Onset
|
Concept
|
Genetic Predisposition to Disease
|
Concept
|
Genomics
|
Concept
|
G-Protein-Coupled Receptor Kinase 2
|
Concept
|
G-Protein-Coupled Receptor Kinase 5
|
Concept
|
Genetic Loci
|
Academic Article
|
Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?
|
Academic Article
|
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
|
Academic Article
|
Cystic and inherited kidney diseases.
|
Academic Article
|
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
|
Academic Article
|
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP).
|
Academic Article
|
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
|
Academic Article
|
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
|
Academic Article
|
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
|
Academic Article
|
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to ß-Blockers in Hypertensive African Americans.
|
Academic Article
|
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.
|
Academic Article
|
Blood pressure in early autosomal dominant polycystic kidney disease.
|
Academic Article
|
Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs.
|
Academic Article
|
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
|
Academic Article
|
Hypertension in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Novel methodology to evaluate renal cysts in polycystic kidney disease.
|
Academic Article
|
Is diabetes mellitus-linked amino acid signature associated with ß-blocker-induced impaired fasting glucose?
|
Academic Article
|
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
|
Academic Article
|
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
|
Academic Article
|
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
|
Academic Article
|
Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic.
|
Academic Article
|
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
|
Academic Article
|
Response to genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
|
Academic Article
|
Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio.
|
Academic Article
|
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide.
|
Academic Article
|
Baseline predictors of central aortic blood pressure: a PEAR substudy.
|
Academic Article
|
Reproducibility of blood pressure response to hydrochlorothiazide.
|
Academic Article
|
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
|
Academic Article
|
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.
|
Academic Article
|
Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects.
|
Academic Article
|
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
|
Academic Article
|
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
|
Academic Article
|
Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.
|
Academic Article
|
A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide.
|
Academic Article
|
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic.
|
Academic Article
|
Renal CD14 expression correlates with the progression of cystic kidney disease.
|
Academic Article
|
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide.
|
Academic Article
|
Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.
|
Academic Article
|
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.
|
Academic Article
|
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Pharmacometabolomics reveals racial differences in response to atenolol treatment.
|
Academic Article
|
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.
|
Academic Article
|
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
|
Academic Article
|
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.
|
Academic Article
|
The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.
|
Academic Article
|
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.
|
Academic Article
|
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
|
Academic Article
|
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
|
Academic Article
|
A Physiologic Approach to the Pharmacogenomics of Hypertension.
|
Academic Article
|
Nephrology fellows show consistent use of, and improved knowledge from, a nephrologist-programmed teaching instrument.
|
Academic Article
|
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
|
Academic Article
|
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.
|
Academic Article
|
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
|
Academic Article
|
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
|
Academic Article
|
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.
|
Academic Article
|
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.
|
Academic Article
|
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
|
Academic Article
|
Volume progression in polycystic kidney disease.
|
Academic Article
|
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study.
|
Academic Article
|
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.
|
Academic Article
|
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response.
|
Academic Article
|
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
|
Academic Article
|
Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension.
|
Academic Article
|
G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension.
|
Academic Article
|
Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide.
|
Academic Article
|
Angiotensin blockade in late autosomal dominant polycystic kidney disease.
|
Academic Article
|
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension.
|
Academic Article
|
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication.
|
Academic Article
|
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
|
Academic Article
|
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
|
Academic Article
|
Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease.
|
Academic Article
|
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
|
Academic Article
|
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
|
Academic Article
|
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.
|
Academic Article
|
Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals.
|
Academic Article
|
Analysis of baseline parameters in the HALT polycystic kidney disease trials.
|
Academic Article
|
Liver involvement in early autosomal-dominant polycystic kidney disease.
|
Academic Article
|
Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
|
Academic Article
|
Mutations in GANAB, Encoding the Glucosidase IIa Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
|
Academic Article
|
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
|
Academic Article
|
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Renal volume in children with ADPKD: size matters.
|
Academic Article
|
Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
|
Academic Article
|
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
|
Academic Article
|
The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease.
|
Academic Article
|
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.
|
Academic Article
|
Reproducibility of Genotypes as Measured by the Affymetrix GeneChip® 100K Human Mapping Array Set.
|
Academic Article
|
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
|
Academic Article
|
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
|
Academic Article
|
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
|
Academic Article
|
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
|
Academic Article
|
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
|
Academic Article
|
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
|
Academic Article
|
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.
|
Academic Article
|
Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease.
|
Academic Article
|
Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
|
Academic Article
|
Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.
|
Academic Article
|
Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease.
|
Academic Article
|
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
|
Academic Article
|
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
|
Academic Article
|
The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Autosomal dominant polycystic kidney disease: time for a change?
|
Academic Article
|
Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Imaging approaches to patients with polycystic kidney disease.
|
Academic Article
|
Polycystic kidney disease: The cadence of kidney growth in ADPKD.
|
Academic Article
|
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.
|
Academic Article
|
The HALT polycystic kidney disease trials: design and implementation.
|
Academic Article
|
Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease.
|
Academic Article
|
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
|
Academic Article
|
Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
|
Academic Article
|
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
|
Academic Article
|
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.
|
Academic Article
|
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.
|
Academic Article
|
Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.
|
Academic Article
|
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
|
Academic Article
|
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.
|
Academic Article
|
Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.
|
Academic Article
|
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
|
Academic Article
|
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
|
Academic Article
|
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
|
Academic Article
|
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
New treatment paradigms for ADPKD: moving towards precision medicine.
|
Academic Article
|
A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.
|
Academic Article
|
Hypoxia-Inducible Factor 1a (HIF-1a), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease.
|
Academic Article
|
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.
|
Academic Article
|
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
|
Academic Article
|
Nurturing passion in a time of academic climate change: the modern-day challenge of junior faculty development.
|
Academic Article
|
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ß-Blockers.
|
Academic Article
|
Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.
|
Academic Article
|
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
|
Academic Article
|
Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
|
Academic Article
|
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.
|
Academic Article
|
Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
|
Academic Article
|
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
|
Academic Article
|
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.
|
Academic Article
|
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
|
Academic Article
|
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
|
Academic Article
|
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
|
Academic Article
|
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
|
Academic Article
|
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
|
Academic Article
|
Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
|
Academic Article
|
Closeout of the HALT-PKD trials.
|
Academic Article
|
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
|
Academic Article
|
Autosomal dominant polycystic kidney disease.
|
Academic Article
|
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
|
Academic Article
|
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
|
Academic Article
|
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.
|
Academic Article
|
Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.
|
Academic Article
|
Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects.
|
Academic Article
|
Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.
|
Academic Article
|
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
|
Academic Article
|
Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study.
|
Academic Article
|
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
|
Academic Article
|
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.
|
Academic Article
|
The future of pharmacogenetics in the treatment of hypertension.
|
Academic Article
|
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
|
Academic Article
|
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.
|
Academic Article
|
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.
|
Academic Article
|
Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
ß2 -Adrenergic Receptor Gene Affects the Heart Rate Response of ß-Blockers: Evidence From 3 Clinical Studies.
|
Academic Article
|
Genome-Wide Meta-Analysis of Blood Pressure Response to ß1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies).
|
Academic Article
|
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers.
|
Academic Article
|
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
|
Academic Article
|
Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients.
|
Academic Article
|
Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.
|
Academic Article
|
A Practical Approach to Polycystic Liver Disease.
|
Academic Article
|
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence.
|
Academic Article
|
Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.
|
Academic Article
|
Polycystins, ADPKD, and Cardiovascular Disease.
|
Academic Article
|
Sorting nexin 1 loss results in increased oxidative stress and hypertension.
|
Academic Article
|
Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.
|
Academic Article
|
Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations.
|
Academic Article
|
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD.
|
Academic Article
|
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
|
Academic Article
|
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
|
Academic Article
|
Advancing Nephrology: Division Leaders Advise ASN.
|
Academic Article
|
Mineral bone disease in autosomal dominant polycystic kidney disease.
|
Academic Article
|
'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study.
|
Academic Article
|
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
|
Academic Article
|
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.
|
Academic Article
|
Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass.
|
Academic Article
|
The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial.
|
Academic Article
|
Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review.
|
Academic Article
|
Tolvaptan in ADPKD Patients With Very Low Kidney Function.
|
Academic Article
|
Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies.
|
Academic Article
|
Agreement of Food Records and 24-Hour Urine Studies in Clinical Practice.
|
Academic Article
|
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
|
Academic Article
|
PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies.
|
Academic Article
|
Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report.
|
Academic Article
|
Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study.
|
Academic Article
|
Emerging Role of Clinical Genetics in CKD.
|
Academic Article
|
Polycystic Kidney Disease in the Real World.
|
Academic Article
|
Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on Hypertension.
|
Academic Article
|
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions.
|
Academic Article
|
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
|
Academic Article
|
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.
|
Academic Article
|
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States.
|
Academic Article
|
Utilization of Cystatin C in the Outpatient Setting.
|
Academic Article
|
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.
|
Academic Article
|
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients.
|
Academic Article
|
Measuring Copeptin, a surrogate for Vasopressin in Patients with Hypertension - Can it identify those who are Volume Responsive?
|
Academic Article
|
Effects of Bardoxolone Methyl in Alport Syndrome.
|
Academic Article
|
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
|
Academic Article
|
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.
|
Academic Article
|
Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation.
|
Concept
|
Emotional Adjustment
|
Concept
|
Patient Reported Outcome Measures
|
Concept
|
Pharmacogenomic Testing
|
Concept
|
Alpha-Ketoglutarate-Dependent Dioxygenase FTO
|
Concept
|
Circulating MicroRNA
|
Concept
|
DCC Receptor
|
Concept
|
Nedd4 Ubiquitin Protein Ligases
|
Concept
|
Bestrophins
|
Concept
|
CRISPR-Cas Systems
|
Concept
|
Observational Studies as Topic
|
Grant
|
Symposium for Molecular and Therapeutic Insights in PKD
|
Grant
|
Limited Competition: Clinical Centers for the HALT-Polycystic Kidney Disease Tria
|
Grant
|
Limited Competition for the Continuation of the Consortium for Radiologic Imaging
|
Academic Article
|
Intracranial Aneurysms in ADPKD: How Far Have We Come?
|
Academic Article
|
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD.
|
Academic Article
|
All Patients with ADPKD Should Undergo Screening for Intracranial Aneurysms: COMMENTARY.
|
Academic Article
|
Pregnancy in Autosomal Dominant Polycystic Kidney Disease.
|
Academic Article
|
Magnetic resonance imaging preprocessing and radiomic features for classification of autosomal dominant polycystic kidney disease genotype.
|
Academic Article
|
Cardiac Localized Polycystin-2 plays a Functional Role in Natriuretic Peptide Production and its Absence Contributes to Hypertension.
|
Academic Article
|
Circulating microRNA Biomarkers of Thiazide Response in Hypertension.
|